Publications by authors named "B Tanenbaum"

Although follicular lymphoma (FL) is traditionally classified as an indolent subtype of B cell non-Hodgkin lymphoma, clinical trajectories are often diverse based on unique disease biology, and many patients will eventually experience relapse of their disease. Furthermore, progression of disease within 24 months is associated with increased mortality rates for FL. In the last five years, we have witnessed an upsurge in the commercial availability of targeted therapies for relapsed/refractory (R/R) FL, including chimeric antigen receptor-T (CAR-T) products, bispecific T cell engagers (BiTEs), epigenetic modifier therapies, and next-generation Bruton tyrosine kinase (BTK) inhibitors.

View Article and Find Full Text PDF

Population-based association studies have identified many genetic risk loci for coronary artery disease (CAD), but it is often unclear how genes within these loci are linked to CAD. Here, we perform interaction proteomics for 11 CAD-risk genes to map their protein-protein interactions (PPIs) in human vascular cells and elucidate their roles in CAD. The resulting PPI networks contain interactions that are outside of known biology in the vasculature and are enriched for genes involved in immunity-related and arterial-wall-specific mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • Aberrations are a critical risk factor for both myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), leading to challenges in distinguishing between the two conditions based on blast thresholds.
  • In a study of 76 patients with aberrations, no significant genomic differences were found between MDS and AML, but overall survival was poor, particularly for certain AML subgroups.
  • Key independent risk factors for mortality identified were having AML over MDS, a complex karyotype, multihit status, and the absence of hematopoietic cell transplant (HCT), suggesting these factors should guide treatment decisions.
View Article and Find Full Text PDF